Loading
Sentiment · FY2026 Q2
As of FY2026 Q1, the Tellvest earnings-call sentiment score for Abbott Laboratories (ABT) is 6/10.
Abbott grew 3.7% on a comparable basis with adjusted EPS of $1.15 up 6%, as the Exact Sciences acquisition added a cancer diagnostics platform while the EP franchise accelerated with dual PFA catheter launches. CGM growth moderated to 7.5% on tender delays and tough comparisons, though the underlying adoption trajectory remained intact. Management set a new guidance range with $5.48 EPS at the midpoint incorporating $0.20 of Exact Sciences dilution, while the Nutrition pricing reset began driving volume recovery.
Scored from Abbott Laboratories’s FY2026 Q1 earnings call. The newest quarter is available with Tellvest Pro.
Full Pro access for 30 days when you create a free account. No credit card required.
All prior quarters are free.
On August 20, 2026, Abbott entered agreements to resolve the Gill lawsuit (a July 2024 Missouri jury awarded $495M, affirmed on appeal in May 2026, ~$600M with interest) plus NEC claims for approximately 2,000 additional infants for an aggregate of about $670 million. Abbott framed the agreements as a compromise of disputed claims, not an admission of liability, and a constructive step toward substantially resolving the necrotizing enterocolitis litigation.
| Quarter | Revenue | Rev YoY | EPS | EPS YoY | Gross margin | Op margin | Net margin | FCF |
|---|---|---|---|---|---|---|---|---|
| FY2024 Q4 | $10.97B | +7.2% | $5.27 | +479.1% | 51.0% | 18.1% | 84.1% | $2.15B |
| FY2025 Q1 | $10.36B | +4.0% | $0.76 | +8.3% | 52.6% | 16.3% | 12.8% | $933M |
| FY2025 Q2 | $11.14B | +7.4% | $1.01 | +36.5% | 56.4% | 18.4% | 16.0% | $1.54B |
| FY2025 Q3 | $11.37B | +6.9% | $0.94 | 0.0% | 55.7% | 18.1% | 14.5% | $2.29B |
| FY2025 Q4 | $11.46B | +4.4% | $1.02 | -80.6% | 57.0% | 19.6% | 15.5% | $2.63B |
| FY2026 Q1 | $11.16B | +7.8% | $0.62 | -18.2% | 56.3% | 16.5% | 9.6% | $916M |
| FY2026 Q2 | $12.59B | +13.0% | $0.53 | -47.5% | 58.0% | 14.2% | 7.4% | — |